Abiopharma

🔍 Jiang Wei (Director)

Company: WATERS CORP /DE/ (WAT)

Report Date: 2025-12-31

Detailed Transactions and Holdings:

• Acquired 60 shares of Common Stock (Direct)
  Date: 2025-12-31 | Code: A | equity_swap_involved: 0 | shares_owned_after: 2,611.27 | transaction_form_type: 4 | Footnotes: F1
• Acquired 307 shares of Common Stock (Direct)
  Date: 2026-01-02 | Code: A | equity_swap_involved: 0 | shares_owned_after: 2,918.27 | transaction_form_type: 4 | Footnotes: F2
• Acquired 828 shares of Stock Option (Right to Buy) at $381.96 per share (Derivative)
  Date: 2026-01-02 | Code: A | Expires: 2036-01-02 | Exercise: 2027-01-02 | equity_swap_involved: 0 | shares_owned_after: 828.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: Represents common stock units received in lieu of cash payment of director fees pursuant to the Issuer's 1996 Non-Employee Director Deferred Compensation Plan. Common stock units are convertible into shares of the Issuer's common stock on a one-for-one basis upon distribution, which will occur on January 1, 2035, pursuant to an election previously made by the Reporting Person.
• F2: Represents shares of common stock subject to restrictions that will lapse with respect to 100% of the shares on January 2, 2027.
• F3: All of the shares of common stock underlying this stock option will vest and become exercisable on January 2, 2027.